Skip to main content
SpringerLink
Log in

Dehydroepiandrosterone in systemic lupus erythematosus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system. The hormone has no known receptor, and consequently, its mechanism of action on immunocompetent cells remains poorly understood. Interestingly, serum levels of DHEA are decreased in patients with inflammatory diseases including lupus, and these levels seem to correlate inversely with disease activity. Following encouraging studies demonstrating beneficial effects of DHEA supplementation in murine lupus models, several clinical studies have tested the effect of DHEA in lupus patients. DHEA treatment could improve overall quality-of-life assessment measures and glucocorticoid requirements in some lupus patients with mild to moderate disease; however, DHEA’s effect on disease activity in lupus patients remains controversial. Long-term safety studies are required in light of the reported effect of DHEA supplementation in lowering high-density lipoprotein cholesterol in lupus patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dillon JS: Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005, 4: 377–385.

    Article  PubMed  CAS  Google Scholar 

  2. Chen CC, Parker CR Jr: Adrenal androgens and the immune system. Semin Reprod Med 2004, 22: 369–377.

    Article  PubMed  CAS  Google Scholar 

  3. Masi AT, Da Silva JA, Cutolo M: Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Baillieres Clin Rheumatol 1996, 10: 295–332.

    Article  PubMed  CAS  Google Scholar 

  4. Hedman M, Nilsson E, de la Torre B: Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 1989, 7: 583–588.

    PubMed  CAS  Google Scholar 

  5. Lahita RG, Bradlow HL, Ginzler E, et al.: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987, 30: 241–248.

    Article  PubMed  CAS  Google Scholar 

  6. Widstrom RL, Dillon JS: Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Semin Reprod Med 2004, 22: 289–298.

    Article  PubMed  CAS  Google Scholar 

  7. Liu D, Dillon JS: Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha (i2,3). J Biol Chem 2002, 277: 21379–21388.

    Article  PubMed  CAS  Google Scholar 

  8. Liu D, Dillon JS: Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004, 69: 279–289.

    Article  PubMed  CAS  Google Scholar 

  9. Ashida K, Goto K, Zhao Y, et al.: Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochim Biophys Acta 2005, 1728: 84–94.

    PubMed  CAS  Google Scholar 

  10. Meikle AW, Dorchuck RW, Araneo BA, et al.: The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992, 42: 293–304.

    Article  PubMed  CAS  Google Scholar 

  11. McLachlan JA, Serkin CD, Bakouche O: Dehydroepiandrosterone modulation of lipopolysaccharide-stimulated monocyte cytotoxicity. J Immunol 1996, 156: 328–335.

    PubMed  CAS  Google Scholar 

  12. Loria RM: Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 2002, 67: 953–966.

    Article  PubMed  CAS  Google Scholar 

  13. Loria RM, Padgett DA: Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol 1992, 127: 103–115.

    Article  PubMed  CAS  Google Scholar 

  14. Jarrar D, Kuebler JF, Wang P, et al.: DHEA: a novel adjunct for the treatment of male trauma patients. Trends Mol Med 2001, 7: 81–85.

    Article  PubMed  CAS  Google Scholar 

  15. Nalbandian G, Kovats S: Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol Res 2005, 31: 91–106.

    Article  PubMed  CAS  Google Scholar 

  16. Kovats S, Carreras E: Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell Immunol 2008 (Epub ahead of print).

  17. Straub RH: The complex role of estrogens in inflammation. Endocr Rev 2007, 28: 521–574.

    Article  PubMed  CAS  Google Scholar 

  18. Olsen NJ, Kovacs WJ: Effects of androgens on T and B lymphocyte development. Immunol Res 2001, 23: 281–288.

    Article  PubMed  CAS  Google Scholar 

  19. Schmidt M, Kreutz M, Loffler G, et al.: Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol 2000, 164: 161–169.

    Article  PubMed  CAS  Google Scholar 

  20. Hammer F, Drescher DG, Schneider SB, et al.: Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. J Clin Endocrinol Metab 2005, 90: 6283–6289.

    Article  PubMed  CAS  Google Scholar 

  21. Raju R, Bland KI, Chaudry IH: Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol Med 2008, 14: 213–221.

    Article  PubMed  CAS  Google Scholar 

  22. Straub RH, Konecna L, Hrach S, et al.: Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998, 83: 2012–2017.

    Article  PubMed  CAS  Google Scholar 

  23. Daynes RA, Araneo BA, Ershler WB, et al.: Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993, 150: 5219–5230.

    PubMed  CAS  Google Scholar 

  24. Delpedro AD, Barjavel MJ, Mamdouh Z, Bakouche O: Activation of human monocytes by LPS and DHEA. J Interferon Cytokine Res 1998, 18: 125–135.

    PubMed  CAS  Google Scholar 

  25. Suzuki T, Suzuki N, Daynes RA, Engleman EG: Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991, 61: 202–211.

    Article  PubMed  CAS  Google Scholar 

  26. Okabe T, Haji M, Takayanagi R, et al.: Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995, 80: 2993–2996.

    Article  PubMed  CAS  Google Scholar 

  27. Murakawa Y, Takada S, Ueda Y, et al.: Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 1985, 134: 187–195.

    PubMed  CAS  Google Scholar 

  28. Solomou EE, Juang YT, Gourley MF, et al.: Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001, 166: 4216–4222.

    PubMed  CAS  Google Scholar 

  29. Tenbrock K, Tsokos GC: Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol 2004, 23: 333–345.

    Article  PubMed  CAS  Google Scholar 

  30. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC: Altered signal transduction in SLE T cells. Rheumatology (Oxford) 2007, 46: 1525–1530.

    Article  CAS  Google Scholar 

  31. Suzuki T, Suzuki N, Engleman EG, et al.: Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995, 99: 251–255.

    Article  PubMed  CAS  Google Scholar 

  32. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998, 273: 32833–32841.

    Article  PubMed  CAS  Google Scholar 

  33. Du C, Khalil MW, Sriram S: Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol 2001, 167: 7094–7101.

    PubMed  CAS  Google Scholar 

  34. Dashtaki R, Whorton AR, Murphy TM, et al.: Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther 1998, 285: 876–883.

    PubMed  CAS  Google Scholar 

  35. Grammer AC, Fischer R, Lee O, et al.: Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004, 6: 28–38.

    Article  PubMed  CAS  Google Scholar 

  36. Lucas JA, Ahmed SA, Casey ML, MacDonald PC: Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 1985, 75: 2091–2093.

    Article  PubMed  CAS  Google Scholar 

  37. Matsunaga A, Miller BC, Cottam GL: Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: lack of an effect on associated immunological abnormalities. Biochim Biophys Acta 1989, 992: 265–271.

    PubMed  CAS  Google Scholar 

  38. Yang BC, Liu CW, Chen YC, Yu CK: Exogenous dehydroepiandrosterone modified the expression of T helper-related cytokines in NZB/NZW F1 mice. Immunol Invest 1998, 27: 291–302.

    Article  PubMed  Google Scholar 

  39. Norton SD, Harrison LL, Yowell R, Araneo BA: Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB/W mice. Autoimmunity 1997, 26: 161–171.

    Article  PubMed  CAS  Google Scholar 

  40. Roubinian JR, Talal N, Greenspan JS, et al.: Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979, 63: 902–911.

    Article  PubMed  CAS  Google Scholar 

  41. Olech E, Merrill JT: DHEA supplementation: the claims in perspective. Cleve Clin J Med 2005, 72: 965–966, 968, 970–971 passim.

    Article  PubMed  Google Scholar 

  42. van Vollenhoven RF, Engleman EG, McGuire JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994, 37: 1305–1310.

    Article  PubMed  Google Scholar 

  43. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL: Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998, 25: 285–289.

    PubMed  Google Scholar 

  44. van Vollenhoven RF, Engleman EG, McGuire JL: Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995, 38: 1826–1831.

    Article  PubMed  Google Scholar 

  45. van Vollenhoven RF, Park JL, Genovese MC, et al.: A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999, 8: 181–187.

    Article  PubMed  Google Scholar 

  46. Formiga F, Moga I, Nolla JM, et al.: The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol 1997, 15: 387–392.

    PubMed  CAS  Google Scholar 

  47. Hartkamp A, Geenen R, Godaert GL, et al.: The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum 2004, 50: 3591–3595.

    Article  PubMed  CAS  Google Scholar 

  48. Chang DM, Lan JL, Lin HY, Luo SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2002, 46: 2924–2927.

    Article  PubMed  CAS  Google Scholar 

  49. Petri MA, Lahita RG, Van Vollenhoven RF, et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002, 46: 1820–1829.

    Article  PubMed  CAS  Google Scholar 

  50. Petri MA, Mease PJ, Merrill JT, et al.: Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004, 50: 2858–2868.

    Article  PubMed  CAS  Google Scholar 

  51. Nordmark G, Bengtsson C, Larsson A, et al.: Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005, 38: 531–540.

    Article  PubMed  CAS  Google Scholar 

  52. van Leuven SI, Kastelein JJ, D’Cruz DP, et al.: Atherogenesis in rheumatology. Lupus 2006, 15: 117–121.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 825 Northeast 13th Street, MS#24, Oklahoma City, OK, 73104, USA

    Amr H. Sawalha

Authors
  1. Amr H. Sawalha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Kovats
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amr H. Sawalha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sawalha, A.H., Kovats, S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr Rheumatol Rep 10, 286–291 (2008). https://doi.org/10.1007/s11926-008-0046-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0046-1

Keywords

Search

Navigation